Health Systems Multi-Cancer Early Detection Solutions

Multi-cancer early detection

The Cancerguard^® test is a multi-cancer early detection (MCED) test that detects more than 50 cancer types and sub-types to help health systems identify cancer signals earlier.1*

Cancer is the #2 cause of death in the US. Which means it’s also a growing challenge for health systems that are committed to finding disease early, treating it effectively, and improving patient outcomes.2

1 in 3

people in the U.S. are projected to develop cancer in their lifetime.3

~70%

of annual cancer cases and deaths are caused by cancers that have no recommended screening options, leaving detection gaps that drive late-stage diagnoses and higher costs.2,4,5 †

Up to 7×

More costly to treat late-stage cancers compared to early-stage treatment.6

Multi-cancer early detection (MCED) testing can help detect hard-to-find cancers in earlier stages when they are more treatable—even before symptoms appear.7 These tests work by analyzing biological signals in the blood, such as DNA methylation patterns, that may indicate the presence of cancer.

A new MCED test from the makers of Cologuard^®, the Cancerguard test complements standard-of-care screening and can help screen for multiple cancers with a simple blood draw.1,7

The only multi‑signal MCED

The only MCED test currently on the market that combines multiple biomarker classes, helping detect a broad range of cancer types across stages7

Expands screening possibilities

Designed to help detect 50+ cancer types and subtypes1*

97.4% specificity

Demonstrates high specificity (97.4%), helping minimize false positives and reduce unnecessary diagnostic testing7‡§

Helps find the most aggressive

Expands early detection opportunities, even for aggressive cancers such as pancreatic, liver, lung, and ovarian2,7

Watch this Modern Healthcare one-on-one episode to find out how MCED tests can open new possibilities in cancer screening and preventive care.

Lab technician in protective gear carefully analyzing test samples in a modern laboratory setting.

20M+ people have been screened with the Cologuard test
Nearly 30 years of advancing cancer diagnostics
The Cancerguard test is supported by data from robust test-development studies involving 20K+ participants, including the first-ever prospective interventional MCED trial8,9,10

The Cancerguard test is designed for seamless system deployment, from order to diagnostic resolution.

Seamless EHR integration

Seamlessly integrates into Aura, HL7 and others for simplified ordering and resulting

Flexible blood collection options

The blood draw can be done in-office, at a laboratory, or via at-home phlebotomy

The Cancerguard DIRECT positive result workflow

The Cancerguard DIRECT (Diagnostic Imaging & Resources for Efficient Cancer Triage) positive workflow was designed to efficiently diagnose cancer or determine if it is not present.10|| Modeling predicted ~30% fewer procedures with imaging-led diagnostic resolution.11

Health system educational resources and tools: Care navigation workflows and a diagnostic resolution guidebook
World-class patient support: Care Navigation services and a Patient Imaging Reimbursement Program of up to $6,000 for non-covered imaging costs for eligible patients¶

Explore Cancerguard

Health care professional in a lab coat smiling while viewing a tablet in a clinical lab.

Advance population health and early detection strategies
Achieve value-based care goals
Integrate cutting-edge innovation with minimal disruption
Scale screening efficiently across care networks

Listen to the HealthLeaders podcast

Find out how the Cancerguard test can enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care.

See it in action

Get a first look at how health systems across the country are preparing for the next era of cancer screening.

Discover how the Cancerguard test can help transform screening in your health system, from earlier detection to reductions in cost of care, all through a simple blood draw.

Two health care professionals collaborating while reviewing clinical data on a computer monitor.

Operationally scalable

Learn how to integrate the Cancerguard test with minimal disruption to your existing workflows.

Health care professional holding a tablet while speaking with a patient.

Expand your screening power

Visit our provider page to get more information about how Cancerguard works and how it can support your team.

Reach out to see how we can support your health system's goals in early cancer detection and diagnosis.

References and footnotes

In internal development studies of adults 50-84 years old, Cancerguard detected signals associated with 50+ cancer types, including their subtypes.
Cancers that have guideline-recommended screening: breast, cervical, colorectal, and lung (high risk).
Performance data presented here was generated from a case-control, test development study of patients 50-84 who were already known to have cancer or to be healthy (no active cancer or suspicion of cancer). It may not accurately reflect the performance in a clinical setting. Real-world specificity may be different compared to case-control data.
False positive and false negative test results can occur.
Adapted from Kisiel, et al. 2024. Diagnostic resolution workflow is based on published expert clinician opinion and results from an exploratory, prospective, interventional study. It is not a replacement for clinical standard of care. There are no established guidelines for imaging following a positive Cancerguard test result. Providers should use their clinical judgment and experience when deciding how to diagnose or treat patients.
Patients must apply. Eligibility depends on program qualifications (which are subject to change) and is not guaranteed. The program will not reimburse any covered imaging costs, including copay, coinsurance, and/or deductible amounts determined by insurance. For more information or to apply, patients should call 1-844-870-8870.

Data on file. Cancerguard Cancer Subtype Analysis. [MED-REF-01259]. Exact Sciences. Madison, WI; September 2025
Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10–45.
American Cancer Society. Cancer Facts & Figures 2025. Accessed December 5, 2025. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf
United States Preventive Services Task Force. A and B recommendations. Published 2022. Accessed December 5, 2025. https://uspreventiveservicest askforce.org/uspstf/recommendation-topics/uspstf-and-b-recommendations
Data on file. Calculated cancers without USPSTF recommended screening tests. 2025. Medical Affairs, Exact Sciences, Madison, WI.
Reddy SR, Broder MS, Chang E, Paydar C, Chung KC, Kansal AR. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285–1294.
Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI.
Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499):1-26.
Douville C, Hogstrom L, Gainullin V, et al. Design and enrollment for a classifier development study for a blood-based multi-cancer early detection (MCED) test. Presented at: ESMO Congress; October 2023; Madrid, Spain. Poster #FPN 189P.
Kisiel JB, Ebbert JO, Taylor WR, et al. Shifting the cancer screening paradigm: developing a multi-biomarker class approach to multi-cancer early detection testing. Life (Basel).2024;14(8):925.
Tyson C, Li KH, Cao X, et al. Tumor localization strategies of multicancer early detection tests: a quantitative assessment. JNCI Cancer Spectrum. 2025;9(2);pkaf011.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

View indications for use

Advancing earlier detection together

The challenge: A rising cancer burden

The solution: Multi-cancer early detection